Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.

@article{Cohen2002ApprovalSL,
  title={Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.},
  author={Martin H. Cohen and John R. Johnson and Ning Li and Gang Chen and Richard Pazdur},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2002},
  volume={8 3},
  pages={665-9}
}
Letrozole (Femara; Novartis Pharmaceuticals Corp., East Hanover, NJ) is a nonsteroidal inhibitor of aromatase enzyme complex. It inhibits the peripheral conversion of circulating androgens to estrogens. In postmenopausal women, letrozole decreases plasma concentrations of estradiol, estrone, and estrone sulfate by 75-95% from baseline with maximal suppression achieved within 2-3 days of treatment initiation. Suppression is dose related, with doses of >or=0.5 mg giving estrone and estrone… CONTINUE READING